Latest Articles about HSP

Back to Neutral on Hospira - Analyst Blog

Zacks Equity Research — Tue, 28 May 2013 22:28:02 Z

We are reverting to a Neutral recommendation on Hospira Inc. ( HSP ) from Underperform. Our target price is $37.00. The stock carries a Zacks Rank #3 (Hold) in the short run. Why the

Earnings Beat at Hospira - Analyst Blog

Mark Vickery — Wed, 01 May 2013 21:10:01 Z

Hospira Inc. 's ( HSP ) first quarter 2013 adjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 44 cents. Higher-than-expected revenues led to the earnings beat.

Brian Rogers of T Rowe Price Buys 4 New Stocks, Including Apple in Q1

Holly LaFon — Thu, 18 Apr 2013 01:09:01 Z

In the quarter ended March 31, 2013, T. Rowe Price's Brian Rogers purchased three new stocks for his fund: Apple ( AAPL ), Western Union ( WU ), Joy Global ( JOY ) and Hospira Inc. (

Bear of the Day: Hospira (HSP) - Bear of the Day

Neena Mishra — Mon, 25 Mar 2013 14:17:01 Z

Hospira has been facing some serious manufacturing quality concerns related its injectable drugs as well as infusion pump systems. Its remediation efforts may be successful in the long-run but

Pediatric Exclusivity for Hospira's Drug - Analyst Blog

Zacks Equity Research — Tue, 19 Mar 2013 21:45:15 Z

Hospira, Inc. ( HSP ) recently gained pediatric exclusivity from the US Food and Drug Administration (FDA) for its injectable sedation drug, Precedex (dexmedetomidine HCl). The FDA's

Bearish MACD for Hospira, Inc. - Tale of the Tape

Zacks Equity Research — Tue, 05 Mar 2013 21:27:01 Z

Hospira, Inc. 's ( HSP ) MACD indicator has moved into bearish territory with a reading of -1.1286. The Zacks Rank # 5 ("Strong Sell") stock decreased more than 0.60% to $29.59 in

Blow for HSP, 2013 View Withdrawn - Analyst Blog

Zacks Equity Research — Tue, 19 Feb 2013 23:50:01 Z

Hospira Inc. 's ( HSP ) shares fell significantly following the import ban imposed by the US Food and Drug Administration (FDA) on some of the company's offerings. Hospira withdrew its

Pre-Market Earnings Report for February 13, 2013 : CMCSA, DUK, DE, TRI, CMCSK, LO, TLM, DPS, CPN, HSIC, HSP, VMI

NASDAQ.com News — Wed, 13 Feb 2013 02:00:04 Z

The following companies are expected to report earnings prior to market open on 02/13/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Comcast Corporation (

Hospira Inks Deal - Analyst Blog

Zacks Equity Research — Fri, 25 Jan 2013 01:14:38 Z

Hospira, Inc. ( HSP ) recently inked a deal with medical devices company Q Core Medical, Ltd. pertaining to the latter's Q Core Sapphire multi-therapy infusion system. The system is a

Hospira traders aim for further gains

David Russell — Wed, 16 Jan 2013 22:20:56 Z

Hospira has been ripping, and one bull expects the gains to continue. optionMONSTER's Heat Seeker tracking program detected the purchase of 6,300 February 35 calls for $1.15 and the sale of

Hospira Downgraded to Strong Sell - Analyst Blog

Zacks Equity Research — Fri, 04 Jan 2013 02:35:01 Z

On January 2, Zacks Investment Research downgraded Hospira, Inc. ( HSP ) to a Zacks #5 Rank (Strong Sell). Why the Downgrade? Hospira is going through a rough patch due to the ongoing

How Hospira bulls are looking for more

David Russell — Fri, 07 Dec 2012 23:20:04 Z

One investor has cleaned up in Hospira and apparently believes that the stock may keep rallying. On Nov. 26, optionMONSTER's Heat Seeker market scanner detected heavy buying in the December

Hospira Tops on All Fronts - Analyst Blog

Mark Vickery — Wed, 07 Nov 2012 21:32:01 Z

Hospira Inc.' s ( HSP ) third quarter 2012 earnings (excluding special items) of 47 cents per share beat the Zacks Consensus Estimate of 45 cents. Higher than expected revenues led to the

Earnings Preview: Hospira - Analyst Blog

Mark Vickery — Tue, 06 Nov 2012 23:30:01 Z

Hospira Inc. ( HSP ) is all set to announce its third quarter 2012 results before the market opens on November 7, 2012. The Zacks Consensus Estimate for the third quarter of 2012 is 45

Hospira in Neutral Lane - Analyst Blog

Zacks Equity Research — Thu, 04 Oct 2012 00:49:23 Z

We are maintaining our Neutral recommendation on Hospira, Inc. ( HSP ) with a target price of $34.00. The stock carries a Zacks #3 Rank (Hold rating) in the short run. Hospira performed